First-in-human phase 2 trial with mite allergoids coupled to mannan in subcutaneous and sublingual immunotherapy.
allergoid
clinical trial
i
mannan
mmunotherapy
polymerized
Journal
Allergy
ISSN: 1398-9995
Titre abrégé: Allergy
Pays: Denmark
ID NLM: 7804028
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
revised:
31
03
2022
received:
19
02
2022
accepted:
20
04
2022
pubmed:
17
5
2022
medline:
1
10
2022
entrez:
16
5
2022
Statut:
ppublish
Résumé
Polymerized allergens conjugated to non-oxidized mannan (PM-allergoids) are novel vaccines targeting dendritic cells (DCs). Previous experimental data indicate that PM-allergoids are readily taken up by DCs and induce Treg cells. This first-in-human study was aimed to evaluate safety and to find the optimal dose of house dust mite PM-allergoid (PM-HDM) administered subcutaneously (SC) or sublingually (SL). In a randomized, double-blind, double-dummy, placebo-controlled trial, 196 subjects received placebo or PM-HDM at 500, 1000, 3000, or 5000 mannan-conjugated therapeutic units (mTU)/mL in 9-arm groups for 4 months. All subjects received 5 SC doses (0.5 ml each) every 30 days plus 0.2 ml SL daily. The primary efficacy outcome was the improvement of titrated nasal provocation tests (NPT) with D. pteronyssinus at baseline and at the end of the study. All adverse events and reactions were recorded and assessed. Secondary outcomes were the combination of symptom and medication scores (CSMS) and serological markers. No moderate or severe adverse reactions were reported. Subjects improving the NPT after treatment ranged from 45% to 62% in active SC, 44% to 61% in active SL and 16% in placebo groups. Statistical differences between placebo and active groups were all significant above 500 mTU, being the highest with 3000 mTU SL (p = 0.004) and 5000 mTU SC (p = 0.011). CSMS improvement over placebo reached 70% (p < 0.001) in active 3000 mTU SC and 40% (p = 0.015) in 5000 mTU SL groups. PM-HDM immunotherapy was safe and successful in achieving primary and secondary clinical outcomes in SC and SL at either 3000 or 5000 mTU/ml.
Sections du résumé
BACKGROUND
Polymerized allergens conjugated to non-oxidized mannan (PM-allergoids) are novel vaccines targeting dendritic cells (DCs). Previous experimental data indicate that PM-allergoids are readily taken up by DCs and induce Treg cells. This first-in-human study was aimed to evaluate safety and to find the optimal dose of house dust mite PM-allergoid (PM-HDM) administered subcutaneously (SC) or sublingually (SL).
METHODS
In a randomized, double-blind, double-dummy, placebo-controlled trial, 196 subjects received placebo or PM-HDM at 500, 1000, 3000, or 5000 mannan-conjugated therapeutic units (mTU)/mL in 9-arm groups for 4 months. All subjects received 5 SC doses (0.5 ml each) every 30 days plus 0.2 ml SL daily. The primary efficacy outcome was the improvement of titrated nasal provocation tests (NPT) with D. pteronyssinus at baseline and at the end of the study. All adverse events and reactions were recorded and assessed. Secondary outcomes were the combination of symptom and medication scores (CSMS) and serological markers.
RESULTS
No moderate or severe adverse reactions were reported. Subjects improving the NPT after treatment ranged from 45% to 62% in active SC, 44% to 61% in active SL and 16% in placebo groups. Statistical differences between placebo and active groups were all significant above 500 mTU, being the highest with 3000 mTU SL (p = 0.004) and 5000 mTU SC (p = 0.011). CSMS improvement over placebo reached 70% (p < 0.001) in active 3000 mTU SC and 40% (p = 0.015) in 5000 mTU SL groups.
CONCLUSIONS
PM-HDM immunotherapy was safe and successful in achieving primary and secondary clinical outcomes in SC and SL at either 3000 or 5000 mTU/ml.
Identifiants
pubmed: 35570712
doi: 10.1111/all.15374
pmc: PMC9796063
doi:
Substances chimiques
Allergens
0
Allergoids
0
Antigens, Dermatophagoides
0
Mannans
0
Vaccines
0
Types de publication
Clinical Trial, Phase II
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3096-3107Informations de copyright
© 2022 Inmunotek SL. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
Références
Breast Cancer Res. 2006;8(3):R27
pubmed: 16776849
Immunotherapy. 2013 Nov;5(11):1177-82
pubmed: 24188672
Curr Opin Allergy Clin Immunol. 2021 Feb 1;21(1):86-99
pubmed: 33369572
Am J Respir Crit Care Med. 2009 Nov 15;180(10):936-47
pubmed: 19696440
J Allergy Clin Immunol. 2022 Jan;149(1):212-222.e9
pubmed: 34153371
Int Arch Allergy Immunol. 2012;157(3):288-98
pubmed: 22041501
Rhinology. 2000 Mar;38(1):1-6
pubmed: 10780040
Curr Treat Options Allergy. 2018;5(3):275-290
pubmed: 30221122
Ann Allergy Asthma Immunol. 1998 Nov;81(5):401-5
pubmed: 9860031
J Allergy Clin Immunol. 2021 Oct;148(4):1061-1071.e11
pubmed: 33819508
Allergol Immunopathol (Madr). 2012 Mar-Apr;40(2):92-9
pubmed: 21550163
J Neuroinflammation. 2008 Sep 29;5:42
pubmed: 18823564
Allergy. 2020 Apr;75(4):746-760
pubmed: 31774179
Allergy. 2011 Oct;66(10):1345-59
pubmed: 21707645
BMC Med Inform Decis Mak. 2020 Jul 7;20(1):150
pubmed: 32635913
Allergy. 2002;57 Suppl 70:5-39
pubmed: 11990714
Clin Ther. 2008 Apr;30(4):573-86
pubmed: 18498908
Glycoconj J. 2016 Feb;33(1):93-101
pubmed: 26603537
Allergo J Int. 2018;27(8):256-262
pubmed: 30546997
Clin Exp Allergy. 2010 Apr;40(4):598-606
pubmed: 20184605
Allergy. 2018 Apr;73(4):765-798
pubmed: 28940458
J Allergy Clin Immunol. 2017 Dec;140(6):1485-1498
pubmed: 29221580
Allergy. 2018 Apr;73(4):875-884
pubmed: 29319882
Allergy. 2019 Aug;74(8):1575-1579
pubmed: 30866053
Allergy. 2019 Dec;74 Suppl 108:3-25
pubmed: 31872476
Allergol Immunopathol (Madr). 2017 Mar - Apr;45(2):198-207
pubmed: 27939406
Immunol Cell Biol. 2004 Oct;82(5):497-505
pubmed: 15479435
Allergy. 2012 Feb;67(2):217-26
pubmed: 22077562
Clin Exp Allergy. 2005 Mar;35(3):313-8
pubmed: 15784109
Allergy. 2006;61 Suppl 82:1-20
pubmed: 16930249
Eur J Health Law. 2000 Jun;7(2):105-21
pubmed: 11789510
Allergy. 2018 Aug;73(8):1597-1608
pubmed: 29377177
Eur Ann Allergy Clin Immunol. 2019 Sep 16;51(5):
pubmed: 31287263
Curr Opin Allergy Clin Immunol. 2020 Dec;20(6):591-601
pubmed: 33002895
Allergy. 2020 Mar;75(3):648-659
pubmed: 31494959
Vet Dermatol. 2018 Oct;29(5):449-e152
pubmed: 30183126
Vet Immunol Immunopathol. 2017 Aug;190:65-72
pubmed: 28778325
Clin Transl Allergy. 2017 Aug 8;7:24
pubmed: 28794855
J Allergy Clin Immunol. 1985 Aug;76(2 Pt 2):397-401
pubmed: 3926854
Allergy. 2022 Oct;77(10):3096-3107
pubmed: 35570712
J Allergy Clin Immunol. 2017 Nov;140(5):1250-1267
pubmed: 28941667
Clin Exp Allergy. 2006 Mar;36(3):261-72
pubmed: 16499636
Allergy. 2007 Mar;62(3):317-24
pubmed: 17298350
J Investig Allergol Clin Immunol. 2011;21(1):1-12; quiz follow 12
pubmed: 21370717
Allergy. 2016 Jan;71(1):99-107
pubmed: 26417901
J Allergy Clin Immunol. 2016 Aug;138(2):558-567.e11
pubmed: 27177779
Curr Allergy Asthma Rep. 2002 May;2(3):245-51
pubmed: 11918867
J Investig Allergol Clin Immunol. 2009;19 Suppl 2:7-13
pubmed: 19530412
Clin Transl Allergy. 2012 Jan 05;2(1):2
pubmed: 22409879
J Grad Med Educ. 2012 Sep;4(3):279-82
pubmed: 23997866
Allergy. 2014 Jul;69(7):854-67
pubmed: 24761804
Immunotherapy. 2013 Feb;5(2):131-3
pubmed: 23413904
World Allergy Organ J. 2014 Mar 28;7(1):6
pubmed: 24679069
Allergy. 2022 Jan;77(1):320-323
pubmed: 34601743
J Allergy Clin Immunol. 2011 Oct;128(4):808-815.e7
pubmed: 21641635